Deposit
Muscle rigidity, very high fever, a circulatory collapse or clouding of consciousness during treatment with Zyprexa® Velotab are symptoms that indicate the occurrence of a malignant neuroepiletic syndrome. This is a life-threatening clinical picture that requires immediate medical treatment. If a malignant neuroleptic syndrome is suspected, treatment with Zyprexa® Velotab is immediately discontinued under medical supervision. If Zyprexa® Velotab is discontinued abruptly, sweating, insomnia, trembling, anxiety disorders or severe nausea can generally occur. If there is a desire to discontinue the therapy with Zyprexa® Velotab, this should be done in consultation with the treating physician.
Interactions
Smoking and consumption of alcohol influences the effect of olanzapine. Therefore, both substances should be avoided during treatment with Zyprexa® Velotab. If Zyprexa® Velotab and antidepressants, other neuroleptics or anticholinergics are taken at the same time, the side effects may be increased.
The effect of dopamine receptor antagonists, which are used to treat Parkinson’s disease, is reduced by Zyprexa® Velotab and the Parkinson’s symptoms can worsen. If Zyprexa® Velotab is taken simultaneously with valproic acid, a drug for the treatment of epilepsy, the risk of white blood cell deficiency (leukopenia) may increase. The effects of opioid painkillers, beta-blockers and antiarrhythmics can be enhanced by Zyprexa® Velotab.
Contraindication
Zyprexa® Velotab should not be taken if there is a known allergy to olanzapine or any other component of the tablets. Also with increased eye pressure (glaucoma) should be refrained from taking. Zyprexa® Velotab is not suitable for children and young people under the age of 18.
Zyprexa® Velotab should not be taken during pregnancy or while breastfeeding. Children whose mothers have taken Zyprexa® Velotab in the last three months of pregnancy may experience symptoms such as movement disorders, tremors, shortness of breath and drowsiness. In this case the newborns must be monitored by a doctor.
Since the active ingredient is detectable in breast milk, it should also be avoided during the breastfeeding period. Women of childbearing age who take Zyprexa® Velotab should use a contraceptive.
